Potential therapy of multidrugresistant and extremely drug-resistant tuberculosis with thioridazine

Leonard Amaral; J Molnar; J Molnar

Potential therapy of multidrugresistant and extremely drug-resistant tuberculosis with thioridazine

Leonard Amaral, J Molnar , J Molnar

Unidade de Parasitologia e Microbiologia Médicas (UPMM)

Research output: Contribution to journal › Article

Abstract

Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high. This mini-review highlights the evidence that supports the use of the phenothiazine neuroleptic thioridazine for the therapy of XDRTB. Although thioridazine does produce some serious side-effects, the poor prognosis associated with an XDRTB infection of a patient that presents with AIDS merits that the use of thioridazine for therapy of XDRTB is seriously considered. A recommended protocol is presented.

Original language	English
Journal	In Vivo
Volume	26
Issue number	2
Publication status	Published - 2012

Fingerprint Dive into the research topics of 'Potential therapy of multidrugresistant and extremely drug-resistant tuberculosis with thioridazine'. Together they form a unique fingerprint.

Cite this

@article{ab08a81b70cb4c6a8b840fe97dda34f9,

title = "Potential therapy of multidrugresistant and extremely drug-resistant tuberculosis with thioridazine",

abstract = "Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high. This mini-review highlights the evidence that supports the use of the phenothiazine neuroleptic thioridazine for the therapy of XDRTB. Although thioridazine does produce some serious side-effects, the poor prognosis associated with an XDRTB infection of a patient that presents with AIDS merits that the use of thioridazine for therapy of XDRTB is seriously considered. A recommended protocol is presented.",

author = "Leonard Amaral and J Molnar and J Molnar",

year = "2012",

language = "English",

volume = "26",

journal = "In Vivo",

issn = "0258-851X",

publisher = "INT INST ANTICANCER RESEARCH",

number = "2",

}

TY - JOUR

T1 - Potential therapy of multidrugresistant and extremely drug-resistant tuberculosis with thioridazine

AU - Amaral, Leonard

AU - Molnar , J

AU - Molnar, J

PY - 2012

Y1 - 2012

N2 - Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high. This mini-review highlights the evidence that supports the use of the phenothiazine neuroleptic thioridazine for the therapy of XDRTB. Although thioridazine does produce some serious side-effects, the poor prognosis associated with an XDRTB infection of a patient that presents with AIDS merits that the use of thioridazine for therapy of XDRTB is seriously considered. A recommended protocol is presented.

AB - Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high. This mini-review highlights the evidence that supports the use of the phenothiazine neuroleptic thioridazine for the therapy of XDRTB. Although thioridazine does produce some serious side-effects, the poor prognosis associated with an XDRTB infection of a patient that presents with AIDS merits that the use of thioridazine for therapy of XDRTB is seriously considered. A recommended protocol is presented.

M3 - Article

C2 - 22351663

VL - 26

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 2

ER -